奥沙利铂
结直肠癌
免疫球蛋白G
抗体
医学
活力测定
癌症
癌症研究
免疫学
药理学
细胞
生物
内科学
生物化学
作者
Yongpeng Shang,Xianbin Zhang,Lixuan Lu,Ke Jiang,Mathias Krohn,Stephanie Matschos,Christina Susanne Mullins,Brigitte Vollmar,Dietmar Zechner,Peng Gong,Michael Linnebacher
标识
DOI:10.1038/s41416-021-01272-6
摘要
Recent evidence proves that intravenous human immunoglobulin G (IgG) can impair cancer cell viability. However, no study evaluated whether IgG application benefits cancer patients receiving chemotherapeutics.Influence of pharmaceutical-grade human IgG on the viability of a series of patient-derived colon cancer cell lines with and without chemotherapeutic intervention was determined. Cell death was analysed flow cytometrically. In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots.We evaluated the effects of pharmaceutical IgG, such as PRIVIGEN® IgG and Tonglu® IgG, in combination with chemotherapeutics. We did not observe any significant effects of IgG on tumour cell viability directly; however, human IgG significantly impaired the anti-tumoral effects of oxaliplatin. Primary cancer cell lines express IgG receptors and accumulate human IgG intracellularly. Moreover, while oxaliplatin induced the activation of ERK1/2, the pharmaceutical IgG inhibited ERK1/2 activity.The present study demonstrates that pharmaceutical IgG, such as PRIVIGEN® IgG and Tonglu® IgG, can impair the anti-carcinoma activity of oxaliplatin. These data strongly suggest that therapeutic IgG as co-medication might have harmful side effects in cancer patients. The clinical significance of these preclinical observations absolutely advises further preclinical, as well as epidemiological and clinical research.
科研通智能强力驱动
Strongly Powered by AbleSci AI